Abstract
daughter cells allowing the maintenance of cell identity. Misregulation of epigenetic processes can cause silencing or ectopic expression of genes and this often leads to disease states. Typically the hallmarks of malignancy are genomic rearrangements and gross morphologies. However, epigenetic misregulation is also typically observed in malignant cells - for example, DNA hypermethylation causing promoter silencing of tumor suppressor genes. Genomics, proteomics, metabolomics and transcriptomics are emerging technologies that are part of the 'Omics' umbrella or high throughput technologies. These are now routinely used in cancer research allowing researchers to determine differences in normal compared to disease states. Ultimately, the premise is that these will improve the screening, diagnosis and treatments of cancers. These emerging technologies, which are considered in this chapter, serve as potential tools in early detection of cancers and for identifying biomarkers for high risk individuals.
| Original language | English |
|---|---|
| Title of host publication | Epigenomic Medicine |
| Editors | Tom C Karagiannis |
| Place of Publication | Kerala, India |
| Publisher | Transworld Research Network |
| Pages | 31-43 |
| Number of pages | 13 |
| ISBN (Print) | 9788178955292 |
| Publication status | Published - 2011 |
Cite this
}
Epigenetic basis of disease. / Venables, Gene; Tuano, Natasha K.; El-Osta, Assam; Karagiannis, Tom C.
Epigenomic Medicine. ed. / Tom C Karagiannis . Kerala, India : Transworld Research Network, 2011. p. 31-43.Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other
TY - CHAP
T1 - Epigenetic basis of disease
AU - Venables, Gene
AU - Tuano, Natasha K.
AU - El-Osta, Assam
AU - Karagiannis, Tom C
PY - 2011
Y1 - 2011
N2 - Epigenetics refers to the inheritance of information contained outside the underlying DNA sequence. Post translational epigenetic modifications including DNA methylation, histone modifications and chromatin remodelling are epigenetically inherited. Epigenetic processes enable organisms to repress various gene sets depending on the cell type and are passed from mother todaughter cells allowing the maintenance of cell identity. Misregulation of epigenetic processes can cause silencing or ectopic expression of genes and this often leads to disease states. Typically the hallmarks of malignancy are genomic rearrangements and gross morphologies. However, epigenetic misregulation is also typically observed in malignant cells - for example, DNA hypermethylation causing promoter silencing of tumor suppressor genes. Genomics, proteomics, metabolomics and transcriptomics are emerging technologies that are part of the 'Omics' umbrella or high throughput technologies. These are now routinely used in cancer research allowing researchers to determine differences in normal compared to disease states. Ultimately, the premise is that these will improve the screening, diagnosis and treatments of cancers. These emerging technologies, which are considered in this chapter, serve as potential tools in early detection of cancers and for identifying biomarkers for high risk individuals.
AB - Epigenetics refers to the inheritance of information contained outside the underlying DNA sequence. Post translational epigenetic modifications including DNA methylation, histone modifications and chromatin remodelling are epigenetically inherited. Epigenetic processes enable organisms to repress various gene sets depending on the cell type and are passed from mother todaughter cells allowing the maintenance of cell identity. Misregulation of epigenetic processes can cause silencing or ectopic expression of genes and this often leads to disease states. Typically the hallmarks of malignancy are genomic rearrangements and gross morphologies. However, epigenetic misregulation is also typically observed in malignant cells - for example, DNA hypermethylation causing promoter silencing of tumor suppressor genes. Genomics, proteomics, metabolomics and transcriptomics are emerging technologies that are part of the 'Omics' umbrella or high throughput technologies. These are now routinely used in cancer research allowing researchers to determine differences in normal compared to disease states. Ultimately, the premise is that these will improve the screening, diagnosis and treatments of cancers. These emerging technologies, which are considered in this chapter, serve as potential tools in early detection of cancers and for identifying biomarkers for high risk individuals.
M3 - Chapter (Book)
SN - 9788178955292
SP - 31
EP - 43
BT - Epigenomic Medicine
A2 - Karagiannis , Tom C
PB - Transworld Research Network
CY - Kerala, India
ER -